Kenvue Inc. $KVUE Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 16.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 174,800 shares of the company’s stock after buying an additional 25,096 shares during the period. SG Americas Securities LLC’s holdings in Kenvue were worth $3,659,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in Kenvue by 4.9% during the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after acquiring an additional 10,600,682 shares in the last quarter. Geode Capital Management LLC increased its stake in Kenvue by 1.2% during the second quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock worth $1,021,267,000 after purchasing an additional 604,953 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Kenvue by 2.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock worth $613,882,000 after purchasing an additional 633,461 shares in the last quarter. Boston Partners boosted its stake in shares of Kenvue by 7.4% in the first quarter. Boston Partners now owns 25,346,453 shares of the company’s stock valued at $606,920,000 after purchasing an additional 1,750,490 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Kenvue by 11.6% in the first quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock valued at $597,395,000 after purchasing an additional 2,597,920 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Up 0.3%

Shares of NYSE KVUE opened at $16.30 on Wednesday. The business has a 50-day moving average of $16.32 and a two-hundred day moving average of $19.93. The company has a market capitalization of $31.22 billion, a price-to-earnings ratio of 21.73, a price-to-earnings-growth ratio of 2.40 and a beta of 0.71. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 5.1%. The ex-dividend date is Wednesday, November 12th. Kenvue’s payout ratio is currently 110.67%.

Analysts Set New Price Targets

KVUE has been the topic of a number of research reports. UBS Group reduced their target price on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, October 8th. Citigroup reduced their price objective on Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. JPMorgan Chase & Co. lowered their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Barclays upped their price target on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Finally, Royal Bank Of Canada decreased their price objective on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.23.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.